Document Detail

Brentuximab vedotin for the treatment of patients with hodgkin lymphoma.
MedLine Citation:
PMID:  24287065     Owner:  NLM     Status:  In-Data-Review    
Hodgkin lymphoma (HL) is a relatively rare but highly curable human cancer. Because very few patients relapse and will require subsequent therapy, new drug development for HL has not been seen as a high priority by the pharmaceutical industry. Brentuximab vedotin, an antibody-drug conjugate that targets CD30 receptors, became the first drug to be approved by regulatory agencies for the treatment of HL in more than 30 years. This review summarizes the current and future directions of incorporating brentuximab vedotin in the management of patients with HL.
Anas Younes
Related Documents :
21083235 - Assessing covalent binding of reactive drug metabolites by complete protein digestion a...
935655 - The distribution of halofenate in plasma: a comparative analysis using scatchard vs. st...
24191905 - Renal cell carcinoma in a patient with rheumatoid arthritis treated with adalimumab.
8468675 - Prediction of drug distribution in distribution dialysis and in vivo from binding to ti...
2222725 - Comparative in vitro dermatokinetics of ibuprofen (ibp).
1372265 - Evaluation of the hepatotoxicological effects of a drug in an in vivo/in vitro model.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hematology/oncology clinics of North America     Volume:  28     ISSN:  1558-1977     ISO Abbreviation:  Hematol. Oncol. Clin. North Am.     Publication Date:  2014 Feb 
Date Detail:
Created Date:  2013-11-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709473     Medline TA:  Hematol Oncol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  27-32     Citation Subset:  IM    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. Electronic address:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.
Next Document:  Combination chemoradiotherapy in early hodgkin lymphoma.